ACS patient with type II diabetes
Conditions
Interventions
Liraglutide will be administrated to the patients with type 2 diabetes within 14 days of onset of ACS. It will be continued for 6 months.
Sponsors
Department of Cardiovascular Medicine, Saga University
Shinkoga hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For entry into the study, participants must meet all of the following criteria. (1) Aged 20 and over (Gender: regardless) (2) type II diabetes (3)Patients who are hospitalized for ACS such as cardiac infarction, unstable angina. (within 14days of onset) (4)Patient with full understanding of this study and agrees with written consent. The agreement must be based on the patients' free will.
Exclusion criteria
Exclusion criteria: Exclusion criteria:patients will be excluded from the study when they meet to any of the criteria. (1)patients with cardiogenic shock (2)patient with serious liver disease((AST)GOT/(ALT)GPT>100) (3)patient with serious kidney trouble.(Cre>5mg/dl and patients under dialysis) (4)Patients with a past history of drug allergy and hypersensitivity. (5)Pregnant and/or breast-feeding at present,or a woman of child-bearing potential. (6)Patients with malignant neoplasms (7)Iinsulin-requiring diabetics.(Type 1,or type 2 with depletion of insulin secretion capacity.) (8)patients who was diagnosed that his/her condition is not appropriate to join this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1)Biomarker of cardiovascular disease (NT-proBNP,high sensitive troponin T,hs-CRP,MCP-1,eGFR,cystatinC,(S)-RAGE,MDA-LDL,AIM,etc) and shift of UACR (2)Changes in left ventricular function (left ventricular ejection rate, left ventricular volume, diastolic function)(3)change in HbA1c,FBS (4)safeness | — |
Countries
Japan
Contacts
Public ContactKoichi Node, MD. PhD.
Saga University Department of Cardiovascular Medicine
Outcome results
None listed